Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients was written by Qu, Changju;Zou, Rui;Wang, Peng;Zhu, Qian;Kang, Liqing;Ping, Nana;Xia, Fan;Liu, Hailing;Kong, Danqing;Yu, Lei;Wu, Depei;Jin, Zhengming. And the article was included in Frontiers in Immunology in 2022.Computed Properties of C16H21Cl2N3O2 The following contents are mentioned in the article:
Chimeric antigen receptor T cell (CAR-T) therapy has emerged as highly effective in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but only about 40% patients have achieved sustained responses. Here, we conducted a phase II clin. trial testing efficacy and toxicities of CAR-T therapy in R/R non-Hodgkin’s lymphoma patients (NCT03196830). Among enrolled patients, 33 R/R DLBCL patients pretreated with DFC (decitabine, fludarabine plus cyclophosphamide) lymphodepletion chemotherapy and infused with tandem CD19-CD22 based CAR-T cells were drawn out for efficacy and toxicities of CAR-T therapy evaluation. With a median follow-up of 10.9(0.6-29.0) months, the best overall response and complete remission (CR) rates were 90.9% and 63.6%, resp. The median progression-free survival (PFS) was 10.2 mo and overall survival (OS) was undefined. The 2- year OS and PFS rates were 54.3% and 47.2%, resp. No severe grade 4 cytokine release syndrome (CRS) was observed and grade 3 CRS was observed in only 7 patients; 3 patients developed mild immune effect or cell-associated neurotoxic syndrome. All toxicities were transient and reversible and no CART-related mortality. Further subgroup anal. showed that achieving CR was an independent prognostic factor associated with favorable PFS and OS. The 2- year OS and PFS for patients who achieved CR within 3 mo (undefined vs. undefined P = 0.021 and undefined vs. undefined P = 0.036) or during the follow-up period were significantly longer than those who did not (undefined vs. 4.6 mo P < 0.0001 and undefined vs. 2.0months P<0.001). While severe CRS was also an independent prognostic factor but associated with inferior PFS and OS. The 2-yr OS and PFS for patients with grade 3 CRS were significantly shorter than those with grade 0-2 CRS (4.1 mo vs. undefined P<0.0001 and 1.7 mo vs. undefined P = 0.0002). This study indicated that CD19/CD22 dual-targeted CAR-T therapy under a decitabine-containing lymphodepletion regimen may be a safe, potent effective approach to R/R DLBCL patients. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Computed Properties of C16H21Cl2N3O2).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Computed Properties of C16H21Cl2N3O2
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem